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 We hope you find the information in this factsheet helpful. If you would like to 
speak with someone about any aspect of MS, contact the MS Trust 
information team and they will help find answers to your questions.  
 
This factsheet has been provided free by the Multiple Sclerosis Trust, a small 
UK charity which works to improve the lives of people affected by MS. We rely 
on donations, fundraising and gifts in wills to be able to fund our services and 
are extremely grateful for every donation received, no matter what size. 
 
MS Trust information service 
 
Helping you find the information you need 
 
The MS Trust offers a wide range of publications, including a newsletter Open 
Door, which provides an ongoing update on research and developments in 
MS management. In addition it contains articles from people with MS and 
health professionals.  
 
For a full list of MS Trust publications, to sign up for Open Door and much 
more visit our website at www.mstrust.org.uk   
 
Freephone 0800 032 3839 (Lines are open Monday – Friday 9am-5pm) 
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This factsheet is aimed at anyone affected by MS who needs basic 
information about Sativex and should be used to support discussion with a 
neurologist, MS nurse or other health professional. 
1.  Introduction 
Sativex was the first cannabis-based medicine to be licensed in the UK. It is 
licensed for use as an add-on treatment for MS-related spasticity (muscle 
stiffness) when people have found that other medicines have not worked well 
or found their side effects intolerable. 
2.  What is Sativex? 
Sativex is a mouth (oromucosal) spray formulated from two chemical extracts 
derived from the cannabis plant and contains delta-9 tetrahydrocannabinol 
(THC) and cannabidiol (CBD).  Cannabis plants are thought to contain more 
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than 60 such chemicals - known as cannabinoids - but these two specific 
cannabinoids have been studied for their effects in MS. 
3.  How does Sativex work? 
The way cannabinoids work is not fully understood but discovery of the 
endocannabinoid system, a natural system of receptors in the human body, 
has provided some insight. Receptors are protein molecules in or on the 
surface of cells to which a substance (such as a drug) can bind, causing a 
change in cell behaviour or activity. The active ingredients of Sativex exert 
their effects upon the CB1 receptor and the CB2 receptor. CB1 receptors are 
thought to exert their effects in the brain while CB2 receptors are thought to 
exert their effects on immune cells.  
4.  Who can be prescribed Sativex? 
The established anti-spasticity drugs, such as baclofen and gabapentin, 
remain the first line treatments for MS spasticity.  If these treatments are not 
working well or have intolerable side effects, Sativex may be considered.  
Sativex is licensed as an add-on therapy – meaning that it will be prescribed 
in combination with other anti-spasticity medications. The addition of Sativex  
means that it may be possible to decrease the dose of other anti-spasticity 
medication and so decrease any troublesome side effects. 
Clinical trials investigating the effects of Sativex on MS spasticity 
demonstrated that those people who experienced improvement (42%) did so 
within four weeks of receiving the medicine1-4. Consequently, Sativex is 
prescribed for a trial period, usually four weeks, in the first instance. If there is 
no clear improvement in spasticity-related symptoms, Sativex will be stopped. 
Treatment with Sativex must be started and supervised by a specialist doctor 
with experience of treating people with MS spasticity such as a neurologist, 
consultant rehabilitation specialist or consultant pain specialist. In some 
areas, GPs can write prescriptions for Sativex but only when instructed to do 
so by the specialist. 
The specialist doctor will conduct a full assessment of the severity of the 
spasticity and an evaluation of the response to standard spasticity treatments 
before considering if the person might benefit from Sativex.  
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5.  How effective is Sativex in treating MS spasticity? 
A phase III trial investigating the effects of Sativex showed that 42% of 
participants had improvements in their spasticity. Amongst those who 
responded, about three quarters had an improvement of greater than 30% in 
their spasticity score3,4  within four weeks when compared with those taking a  
placebo. Combined analysis of three clinical trials confirmed the effectiveness 
of Sativex 5. 
6.  How often is Sativex taken? 
Sativex is sprayed into the mouth either on the inside of the cheek or under 
the tongue. The severity of spasticity symptoms varies from one person to 
another so the number of sprays needed depends on the individual. At the 
start of treatment, the prescribing doctor will advise on frequency and timing 
of  mouth sprays and may suggest a gradual increase until the most effective 
dose is found.  
The maximum dose of Sativex is 12 sprays per day. A gap of at least 15 
minutes should be left between sprays. The doses can be spread over the 
day in a way that suits you. The effectiveness of treatment should be 
assessed from time to time to see if you should carry on taking it. 
7.  What are the side effects?  
You must not drive or use machinery when you first start Sativex and until you 
are on a regular daily dose. 
The most common side effects are feeling sleepy or dizzy. These tend to 
occur in the first four weeks of treatment and wear off over time. Side effects 
can also be reduced by taking fewer sprays or waiting longer between sprays. 
People who experience any significant side effects should not drive, operate 
machinery or take part in any activity that could prove hazardous. 
Studies into long-term use of Sativex in people with MS showed that sudden 
discontinuation of treatment did not result in any significant withdrawal-like 
symptoms. Some people reported temporary changes in their sleeping 
patterns, mood or appetite following discontinuation.  The lack of withdrawal 
symptoms suggest that dependence on the treatment is highly unlikely6,7. 
Sativex did not affect cognition or induce any psychopathological symptoms8. 
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8.  Does Sativex interact with other medicines? 
The prescribing doctor should be made aware of all other medications that the 
person is taking including over the counter and herbal medicines.  Particular 
care should be taken if this includes any sleeping pills, sedatives or other 
drugs with sedative effects as combining these medicines with Sativex may 
cause increased sleepiness.   
Care should be taken as a reduction in muscle tone and power can occur with 
Sativex and may lead to a greater risk of falls.  
Sativex may interact with alcohol and can affect coordination, concentration 
and the ability to respond quickly. 
9.  Who should not be prescribed Sativex? 
People should not be prescribed Sativex if they: 
 Have an allergy to cannabinoids or the other ingredients of Sativex – 
propylene glycol, ethanol and peppermint oil 
 Have a known or suspected personal history or family history of 
schizophrenia, psychosis or other significant psychiatric disorder. This 
does not include depression which is part of the person’s MS 
symptoms.  
 Are breastfeeding. 
People should check with their doctor or pharmacist if they: 
 Are under 18 years of age 
 Have epilepsy or regular fits (seizures) 
 Have liver, kidney or heart problems 
 Are elderly, due to the increased risk of falls 
 Have previously abused any drug or substance 
 Are pregnant or plan to become pregnant. Sativex should not be used 
unless the doctor believes the benefits of treatment outweigh the 
potential risks posed to the baby.   
 Both men and women receiving Sativex should use effective 
contraception during treatment and for three months after stopping.   
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10.  Funding of Sativex 
Sativex has not yet been assessed by NICE (the National Institute for Health 
and Clinical Excellence) but is being included in the review of Clinical 
Guideline 8, Multiple sclerosis: management of multiple sclerosis in primary 
and secondary care.  A decision is expected in 2014. 
Until then, funding decisions are made locally by the relevant NHS authorities 
according to local priorities and budgets. This means that funding is not 
always available.  
In areas where Sativex is not routinely funded, specialists may submit an 
individual funding request (IFR) if they can make the case that the individual 
will benefit. IFRs are not always granted, meaning that some people opt to 
pay for Sativex themselves. The cost of fulfilling a private prescription varies 
widely depending on the pharmacy so it is worth calling around for the best 
price. 
In April 2011, the Scottish Medicines Consortium (SMC), which plays the 
equivalent role to NICE for the NHS in Scotland, announced that it was unable 
to recommend Sativex within the NHS in Scotland as it had not received a 
submission from the holder of the marketing authorisation. However, an 
individual patient treatment request (IPTR) can be made. 
11.  Travelling abroad with Sativex? 
Sativex is a controlled drug and its legal status varies between countries. 
People taking Sativex should check its legal status in the countries to which 
they are travelling by contacting the Embassy, Consulate or High Commission 
of each country for information about the rules on carrying controlled drugs. 
Driving while taking Sativex may be illegal in some countries. 
People leaving the UK will not need a Home Office license if they are 
travelling for less than three months or carrying less than three months supply 
of medicine. However, they will need a letter from their prescribing doctor that 
includes: 
 Name, address, date of birth 
 outward and return dates of travel 
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 the countries being visited 
 the name, total amount and strength of the medicine being carried. 
12.  Clinical trials of Sativex 
Sativex has been studied for its effects on a number of MS-related symptoms 
including spasticity and spasms, pain, bladder symptoms9, tremor, and sleep 
disturbance. 
Sativex is still in development as a possible treatment for cancer pain and 
neuropathic pain, including in MS. 
13.  Legal position of cannabis 
Sativex was the first cannabis-based medicine to be licensed in the UK so the 
legal arrangements for prescribing and using this particular form of cannabis 
are exceptional. 
In contrast, 'street' cannabis is an illegal drug and is not currently recognised 
in law as having any medicinal value. The penalties for possessing or using 
cannabis are significant. Recent legal cases have indicated that the law 
makes no exception for people using or supplying cannabis to help relieve 
medical symptoms. 
Cannabis and its derivatives are being tested in ongoing clinical trials. More 
information is available on the MS Trust website in the 'cannabis' entry of the 
A to Z of MS. 
 
For further information on spasticity see the MS Trust’s Spasticity and 
Spasms factsheet. 
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